The DOI matches its Crossref record; 202 of the 202 references it cites were found in a registry or an index; 252 of the 329 sources its claims cite were checked for support.
Microglial function, INPP5D/SHIP1 signaling, and NLRP3 inflammasome activation: implications for Alzheimer’s disease
Open accessAbstract
Recent genetic studies on Alzheimer’s disease (AD) have brought microglia under the spotlight, as loci associated with AD risk are enriched in genes expressed in microglia. Several of these genes have been recognized for their central roles in microglial functions. Increasing evidence suggests that SHIP1, the protein encoded by the AD-associated gene INPP5D, is an important regulator of microglial phagocytosis and immune response. A recent study from our group identified SHIP1 as a negative regulator of the NLRP3 inflammasome in human iPSC-derived microglial cells (iMGs). In addition, we found evidence for a connection between SHIP1 activity and inflammasome activation in the AD brain. The NLRP3 inflammasome is a multiprotein complex that induces the secretion of pro-inflammatory cytokines as part of innate immune responses against pathogens and endogenous damage signals. Previously published studies have suggested that the NLRP3 inflammasome is activated in AD and contributes to AD-related pathology. Here, we provide an overview of the current understanding of the microglial NLRP3 inflammasome in the context of AD-related inflammation. We then review the known intracellular functions of SHIP1, including its role in phosphoinositide signaling, interactions with microglial phagocytic receptors such as TREM2 and evidence for its intersection with NLRP3 inflammasome signaling. Through rigorous examination of the intricate connections between microglial signaling pathways across several experimental systems and postmortem analyses, the field will be better equipped to tailor newly emerging therapeutic strategies targeting microglia in neurodegenerative diseases.
Overview
CoChat Summary
TL;DR
This narrative review synthesizes evidence that SHIP1, encoded by the Alzheimer's disease (AD) risk gene INPP5D, acts as a negative regulator of microglial activation and of the NLRP3 inflammasome, and proposes that reduced SHIP1 activity links phosphoinositide signaling, phagocytic receptor pathways (TREM2, TLR4, FcγR, CR3, TAM receptors), and inflammasome-driven neuroinflammation in AD. It argues that SHIP1's effects are context- and disease-stage-dependent, leaving open whether therapeutic strategies should aim to increase or decrease SHIP1 activity.
Key findings
- The authors' group previously found that acute pharmacological inhibition of SHIP1 phosphatase activity or genetic loss of one copy of INPP5D in human iPSC-derived microglia (iMGs) induced IL-18 and IL-1β secretion that was blocked by the NLRP3 inhibitor MCC950 and by caspase-1 inhibitors; despite increased cytokine secretion, pro-IL-1β mRNA was lowered, suggesting SHIP1 reduction promotes the activation step while feedback-inhibiting the priming step.
- In post-mortem AD brain, lower aqueous-soluble SHIP1 levels were significantly associated with elevated IL-18 protein, and lower SHIP1 immunoreactivity correlated with a higher percentage of microglia containing ASC specks; SHIP1 localization shifted from diffuse to punctate patterns, and mass spectrometry showed reduced peptides encoding the SHIP1 phosphatase domain in AD brain.
- NLRP3 inflammasome activation is implicated in AD pathology: Aβ (fibrillar and oligomeric) and aggregated tau activate the inflammasome, ASC specks can cross-seed Aβ aggregation, and Nlrp3 or Casp1 ablation in APP/PS1 mice rescued spatial memory, LTP suppression and spine loss and decreased plaque deposition, while MCC950 reduced plaque numbers and improved cognition in APP/PS1 mice.
- Mouse studies of Inpp5d reduction show largely beneficial effects (increased phagocytosis of apoptotic neurons and Aβ42, increased plaque-associated microglia, plaque compaction, rescued spontaneous alternation in 5xFAD), but effects on plaque burden are contradictory across studies (increased, decreased, or unchanged depending on model and timing).
Methods
- Narrative review; no primary experiments reported. The authors synthesize published human post-mortem, human iPSC-derived microglia, and rodent model literature, including their own prior study (Chou et al., Nat Commun 2023).
- Scope: microglial biology, NLRP3 inflammasome assembly and two-step activation, phosphoinositide/PI3K-Akt signaling, SHIP1 domain structure and post-translational regulation, SHIP1 interactions with TREM2/DAP12, TLR4/MyD88, NOD2, FcγRIIA/IIB, CR3 and TAM receptors, INPP5D genetics and isoform expression, and consequences of microglial inflammasome activation on neurons, astrocytes and oligodendrocytes.
- No systematic search strategy, inclusion criteria, or quantitative synthesis is described.
Limitations
- Stated by the paper: evidence on whether to increase or decrease SHIP1 activity is "seemingly contradictory"; the authors attribute divergent mouse plaque-load results to differences in disease stage at which Inpp5d is reduced and to differences among AD mouse models, and note possible genuine species differences or unknown extenuating factors.
- Stated by the paper: it is unclear whether and how the AD-associated INPP5D SNPs (rs35349669, rs10933431, rs7597763, rs61068452) affect INPP5D mRNA levels or splicing; one study found increased expression of a truncated isoform lacking the phosphatase domain, so increased INPP5D expression may not mean increased SHIP1 activity.
- Stated by the paper: methods to measure SHIP1 activity in microglia in postmortem brain are lacking, and further studies are needed; the authors also note that astrocyte-state studies relied on the binary "A1/A2" framework, which does not capture astrocyte diversity.
- Evident from the text: as a narrative review it presents no new data, and several key mechanistic claims (e.g., SHIP1 inhibition of TREM2 signaling) derive from non-microglial cells such as osteoclasts and macrophages, with the authors noting that mechanisms in microglia remain to be clarified.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures
![Fig. 1 NLRP3 inflammasome activation involves two steps. In the priming step, activation of TLR4, TNFR or IL-1R1 leads to activation of NF-kB, which subsequently translocates to the nucleus and induces the transcription of pro-IL-1β, ASC (also known as PYCARD) and NLRP3. NLRP3 is autoinihibted in the cytosol and remains in the autoinhibited state after the priming step. An activating signal is necessary to release the autoinhibition. Activated NLRP3 can undergo oligomerization through homotypic NACHT domain interactions to form the inflammasome complex. NLRP3 oligomers induce the filament assembly of ASC (PYCARD) into ASC specks through homotypic PYD interactions. ASC specks act as a molecular platform to recruit pro-caspase-1 through homotypic CARD interactions. Pro-caspase-1 undergoes autoproteolysis to generate active caspase-1, which can cleave pro-forms of IL-1β and IL-18 into their mature forms. Caspase-1 can also cleave gasdermin D (GSDMD) into its N-terminal fragment (GSDMD-N), which translocates to the plasma membrane and forms a pore, through which IL-1β and IL-18 are released into the extracellular space (ECS). NLRP3, nucleotide-binding domain (NOD)-like receptor protein 3; ASC, apoptosis-associated speck-like protein; PYD, pyrin-like domain; CARD, caspase recruitment domain; LRR, leucine-rich repeat. Figure created in BioRender.com [55, 61, 62]](/paper-figures/7a131405cb5947cfa9538e6945cfc1dc/microglial-function-inpp5d-ship1-signaling-and-nlrp3-inflammasome-activation-figure-1.jpg)
![Fig. 2 SHIP1 is a phosphatase involved in phosphoinositide signaling. Activation of a receptor tyrosine kinase (RTK) recruits the p85 subunit of phosphotidylinositol-3 kinase (PI3K). PI3K generates PI(3,4,5)P3 at the plasma membrane by phosphorylating PI(4,5)P2. SYNJ1 can dephosphorylate PI(4,5)P2 back into its precursor, PI4P. PI(3,4,5)P3 can activate Akt, which can activate various downstream targets, one of which is IKKα of the IKK kinase complex. IKKα activation leads to phosphorylation of IkB, followed by the ubiquitin-mediated proteasomal degradation of IkB, which enables the NF-kB complex to translocate to the nucleus. The NF-kB complex can activate the transcription of its numerous target genes, including genes involved in immune response. SHIP1 can negatively regulate PI3K/Akt signaling. SHIP1 binds to PI(3,4,5)P3 via its PH-L domain and dephosphorylates PI(3,4,5)P3 via its 5’ phosphatase catalytic domain to generate PI(4,5)P2. C2 domain of SHIP1 can bind to PI(4,5)P2, which is thought to allosterically regulate SHIP1’s phosphatase activity. SH2 domain can dock onto phosphorylated tyrosine residues to regulate the activity of receptors containing immunoreceptor tyrosine activating/inhibiting motif (ITAMs/ITIMs). This domain is also important for SHIP1’s localization within the cell. SHIP1 can be phosphorylated at Ser440 within the 5’ phosphatase domain by PKA to increase the phosphatase activity. Phosphorylation of SHIP1 at Tyr1022 within the NPxY motif allows binding with SHIP1’s own SH2 domain, which may mediate its dimerization or oligomerization. ECS, extracellular space; SH2, src homology 2, PH-L, plectrin homology-like. Figure created in BioRender.com [87, 88, 91, 106, 107, 128]](/paper-figures/98c8e6412d024a69be831bd5caabf637/microglial-function-inpp5d-ship1-signaling-and-nlrp3-inflammasome-activation-figure-2.jpg)
![Fig. 3 SHIP1 regulates multiple receptors expressed in microglia and the microglial NLRP3 inflammasome. (A) TREM2 activation recruits p85 subunit of PI3K to the immunoreceptor tyrosine activating motif (ITAM) of DAP12. SHIP1 inhibits downstream activity of TREM2/DAP12 by binding to the immunoreceptor tyrosine activating motif (ITAM) of DAP12, preventing the association of p85 with DAP12, in osteoclasts. (B) SHIP1 inhibits the association of TLR4 with its adaptor protein MyD88 in macrophages. TLR4/MyD88 signaling leads to activation of NF-kB by inducing degradation of IΚB, which is also inhibited by SHIP1. (C) SHIP1 inhibits phagocytosis mediated by CR3 and FCγRIIA in macrophages. SHIP1 binds to the ITAM of FCγRIIA, inhibiting the downstream PI3K signaling. SHIP1 can also bind to the immunoreceptor tyrosine inhibitory motif (ITIM) of the inhibitory receptor FCγRIIB, which enhances FCγRIIB-mediated inhibition of phagocytosis. The exact mechanism of how SHIP1 inhibits CR3 is currently unknown. (D) SHIP1 inhibits the activation of the NLRP3 inflammasome. Pharmacological inhibition of SHIP1 or genetic reduction of INPP5D activates the NLRP3 inflammasome in human iPSC-derived microglial cells (iMGs), resulting in increased secretion of IL-1β and IL-18. On the other hand, loss of SHIP1 inhibits the upregulation of pro-IL-1β, suggesting that reduction of SHIP1 activity may induce inflammasome activation while inhibiting the priming step in some contexts. ECS, extracellular space. Figure created in BioRender.com [114, 121, 137, 138, 161, 197]](/paper-figures/023045a007a24c289c8db1e89f0d18f3/microglial-function-inpp5d-ship1-signaling-and-nlrp3-inflammasome-activation-figure-3.jpg)
Verification
Claims the paper makes
145 Valid · 14 Not valid · 30 Not checked · 29 Own results and interpretations
At least one cited source doesn’t support this claim or points to a different paper, and none confirmed it — see the verdicts below.
In the paper
“In accord, overexpression of INPP5D in iMGs showed an elevation in RNA levels of NF-kB pathway genes, suggesting that microglia from AD brains may display changes relevant to reduced SHIP1 activity [161].”
§ Microglial function, INPP5D/SHIP1 signaling, and NLRP3 inflammasome activation: implications for Alzheimer’s disease > Complex SHIP1 post-transcriptional regulation in AD
What the sources say
- Disputedcites [161] Chou V, Pearse RV, Aylward AJ et al. INPP5D regulates inflammasome activation in human microglia. Nat Commun. 2023. sourceExperimental — accuracy not yet measured
The section on acute INPP5D inhibition (page unavailable) reports increased NF-κB pathway activity after treating iMGLs with 3AC, an INPP5D inhibitor. It does not report this elevation after INPP5D overexpression; the claimed direction of manipulation is opposite to the one studied. (LLM, conf=0.88)
Checked by a reasoning model — may be wrong.
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Disputed
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Recent genetic studies on Alzheimer’s disease (AD) have brought microglia under the spotlight, as loci associated with AD risk are enriched in genes expressed in microglia.”
- Also stated in: § Background · plain
“Many of these loci are in the vicinity of genes that are strongly expressed in microglia and implicated in microglial functions, including ABCA7, ABI3, APOE, CD2AP, CD33, CLU, CR1, EPHA1, HLA-DRB5/DBR1, MS4A6A/MS4A6E, PLCG2, SORL1, TREM2 and INPP5D [3–11].”
§ Microglial function, INPP5D/SHIP1 signaling, and NLRP3 inflammasome activation: implications for Alzheimer’s disease > Abstract
What the sources say
- Partly supportedcites [3] Sims R, van der Lee SJ, Naj AC, et al. Rare coding variants in PLCG2, ABI3, and TREM2 implicate microglial-mediated innate immunity in Alzheimer’s Disease. Nat Genet. 2017;49:1373–84. sourceExperimental — accuracy not yet measured
The Abstract reports that three AD-associated variants occur in genes highly expressed in microglia, and identifies other known AD loci with a similar expression pattern. It also reports enrichment of AD association signals in an immune-related gene network, but does not establish the broader claim that AD-risk loci as a group are enriched specifically in microglia-expressed genes. (LLM, conf=0.82)
- Partly supportedcites [4] Dalmasso MC, Brusco LI, Olivar N, et al. Transethnic meta-analysis of rare coding variants in PLCG2, ABI3, and TREM2 supports their general contribution to Alzheimer’s Disease. Transl Psychiatry. 2019;9:1–6. sourceExperimental — accuracy not yet measured
The Introduction (page not provided) says four rare AD-associated variants are involved in microglial-mediated innate immunity, supporting a link between AD genetics and microglia. It does not report that AD-risk loci are enriched in genes expressed in microglia; that broader enrichment claim is unsupported by this paper's text. (LLM, conf=0.84)
- Supportedcites [5] Efthymiou AG, Goate AM. Late onset Alzheimer’s Disease genetics implicates microglial pathways in Disease risk. Mol Neurodegener. 2017;12:1–12. source
The ‘AD-risk genes in microglia’ section describes genes within AD-risk loci that are expressed in microglia. The Background also says genetic and gene-network findings converge on enriched immune and myeloid contributions to AD. Together, these support the citing sentence’s broad paraphrase; the paper does not give a numerical enrichment estimate here. (LLM, conf=0.86)
- Supportedcites [6] McQuade A, Blurton-Jones M. Microglia in Alzheimer’s Disease: exploring how Genetics and phenotype influence risk. J Mol Biol. 2019;431:1805–17. source
The Genome-wide Association Studies section reports that around two thirds of newly identified AD-risk SNPs are in genes expressed exclusively or most highly in microglia. This supports the claim that AD-risk loci are enriched in microglia-expressed genes. (LLM, conf=0.94)
- Not checked — no full text of the sourcecites [7] Scheiblich H, Trombly M, Ramirez A, et al. Neuroimmune connections in aging and neurodegenerative Diseases. Trends Immunol. 2020;41:300–12. source
- Supportedcites [8] Wightman DP, Jansen IE, Savage JE, et al. A genome-wide association study with 1,126,563 individuals identifies new risk loci for Alzheimer’s Disease. Nat Genet. 2021;53:1276–82. source
The ‘Tissue type, cell type and gene-set enrichment’ section reports that expression of LOAD-associated genes was significantly associated with six single-cell datasets and that microglia were the only significant cell type in all six. It explicitly describes this as enrichment in nonhuman and human microglia, supporting the cited claim. (LLM, conf=0.94)
- Partly supportedcites [9] Lambert JC, Ibrahim-Verbaas CA, Harold D, et al. Meta-analysis of 74,046 individuals identifies 11 new susceptibility loci for Alzheimer’s Disease. Nat Genet. 2013;45:1452–8. sourceExperimental — accuracy not yet measured
The passage labeled Abstract reports Alzheimer’s risk loci and says several candidate genes fall in immune-response and inflammation pathways enriched for GWAS association signals. It does not say that risk loci are enriched in genes expressed in microglia; the enrichment described is for pathways, not microglial gene expression. (LLM, conf=0.83)
- Supportedcites [10] Kunkle BW, Grenier-Boley B, Sims R, et al. Genetic meta-analysis of diagnosed Alzheimer’s Disease identifies new risk loci and implicates Aβ, tau, immunity and lipid processing. Nat Genet. 2019;51:414–30. source
The Results section (‘Candidate gene prioritization at genome-wide loci’) reports that 38 genes at genome-wide AD-associated loci belong to a set preferentially expressed in aged microglia, and that the set is enriched for Alzheimer’s disease genes. This supports the citing sentence’s paraphrase; the passage does not provide a page number. (LLM, conf=0.91)
- Supportedcites [11] Bellenguez C, Küçükali F, Jansen IE, et al. New insights into the genetic etiology of Alzheimer’s Disease and related Dementias. Nat Genet. 2022;54:412–36. source
The Pathway analyses section reports that microglial gene expression was significantly enriched for association with Alzheimer’s disease and related dementias (ADD) risk: greater expression corresponded to a more significant genetic association. The Discussion likewise says the single-cell analysis highlighted genes expressed in microglia. Page numbers are not available in the supplied copy. (LLM, conf=0.91)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Also stated in: § Background · plain
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Levels of these pro-inflammatory cytokines (including IL-1β, IL-6, IL-8, IL-18 and TNF) are upregulated in serum, cerebrospinal fluid (CSF) and post-mortem brain tissue of AD patients [23–25].”
§ Microglial function, INPP5D/SHIP1 signaling, and NLRP3 inflammasome activation: implications for Alzheimer’s disease > Role of inflammation in AD
What the sources say
- Not matchedcites [23] Wang WY, Tan MS, Yu JT, et al. Role of pro-inflammatory cytokines released from microglia in Alzheimer’s Disease. Ann Transl Med. 2015;3:136.
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- Could not verifycites [24] Higginbotham L, Ping L, Dammer EB et al. Integrated proteomics reveals brain-based cerebrospinal fluid biomarkers in asymptomatic and symptomatic Alzheimer’s disease. Sci Adv.; 6. sourceExperimental — accuracy not yet measured
The Results section reports altered CSF proteins and identifies osteopontin as a pro-inflammatory cytokine linked to AD, but it does not establish increases in the five cytokines named in the claim. Searches for IL-1β, IL-6, IL-8, IL-18, TNF, and the serum/CSF/post-mortem-brain comparison found no passage addressing that specific claim. Page numbers were not available in our copy. (LLM, conf=0.72)
- Partly supportedcites [25] Brosseron F, Krauthausen M, Kummer M, et al. Body fluid cytokine levels in mild cognitive impairment and Alzheimer’s Disease: a comparative overview. Mol Neurobiol. 2014;50:534. sourceExperimental — accuracy not yet measured
The Results sections on IL-1β, IL-6, TNF-α and IL-18 report elevated levels in some AD studies, but also unchanged or decreased levels; IL-1β is mostly reported as unchanged in CSF. The paper reviews blood and CSF findings, not the claimed upregulation in post-mortem brain tissue. Page numbers are unavailable in our copy. (LLM, conf=0.90)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Not matched
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“Aging, which remains the largest risk factor for LOAD, is associated with low-grade systemic inflammation (termed “inflammaging”) [20, 21].”
§ Microglial function, INPP5D/SHIP1 signaling, and NLRP3 inflammasome activation: implications for Alzheimer’s disease > Role of inflammation in AD
What the sources say
- Supportedcites [20] Franceschi C, Garagnani P, Parini P, et al. Inflammaging: a new immune–metabolic viewpoint for age-related Diseases. Nat Rev Endocrinol. 2018;14:576–90. source
The Introduction (p. 5) defines inflammaging as chronic, low-grade inflammation occurring during ageing. The Similarities section (p. 16) describes its pro-inflammatory effect as systemic. (LLM, conf=0.93)
- Not checked — no full text of the sourcecites [21] Hou Y, Dan X, Babbar M, et al. Ageing as a risk factor for neurodegenerative Disease. Nat Rev Neurol. 2019;15:565–81. source
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“In the second, activation step, the now primed NLRP3 inflammasome can be directly activated by any of the various signals including ATP, reactive oxygen species (ROS) and DNA released from damaged mitochondria, protein aggregates, uric acid crystals and ceramide, bacterial or viral RNA, airborne pollutants such as asbestos and silica, decreased intracellular concentrations of K+ and Cl− as well as”
§ Microglial function, INPP5D/SHIP1 signaling, and NLRP3 inflammasome activation: implications for Alzheimer’s disease > The inflammasome is a multiprotein complex involved in activation of inflammatory responses
What the sources say
- Partly supportedcites [57] Hornung V, Bauernfeind F, Halle A, et al. Silica crystals and aluminum salts activate the NALP3 inflammasome through phagosomal destabilization. Nat Immunol. 2008;9:847–56. sourceExperimental — accuracy not yet measured
The Introduction and Results identify ATP, uric acid crystals and silica as NALP3 activators, and the Discussion discusses asbestos and potentially aggregated proteins. The copy does not establish mitochondrial DNA, ceramide, decreased chloride or calcium flux as activators. It also cautions that low intracellular potassium may be required but insufficient for activation, and that direct recognition of the diverse stimuli is only one possible mechanism. (LLM, conf=0.90)
- Partly supportedcites [58] Swanson Kv, Deng M, Ting JPY. The NLRP3 inflammasome: molecular activation and regulation to therapeutics. Nat Rev Immunol. 2019;19:477–89. sourceExperimental — accuracy not yet measured
The NLRP3 activation, K+ efflux, Lysosomal disruption, Mitochondria, and Ca2+ flux sections (pages unavailable) support a second activation step involving ATP, mitochondrial ROS and oxidized DNA, uric acid crystals, silica, asbestos, ion efflux, and sometimes Ca2+ flux. They describe these largely as stimuli or upstream pathways, not as agents that all directly activate NLRP3; the role of Ca2+ flux is explicitly debated. The passages found do not substantiate ceramide or protein aggregates as activation signals. (LLM, conf=0.88)
- Partly supportedcites [59] Scheiblich H, Schlütter A, Golenbock DT, et al. Activation of the NLRP3 inflammasome in microglia: the role of ceramide. J Neurochem. 2017;143:534–50. sourceExperimental — accuracy not yet measured
The title in the indexed citation record (no section or page supplied) links ceramide to NLRP3 inflammasome activation in microglia. The retrieved passages do not establish that ceramide directly activates the primed inflammasome or support the claim's list of other signals, including ATP, mitochondrial DNA, ion changes, and Ca²⁺ flux. (LLM, conf=0.70)
- Partly supportedcites [60] Dostert C, Pétrilli V, Van Bruggen R, et al. Innate immune activation through Nalp3 inflammasome sensing of asbestos and silica. Science. 2008;320:674–7. sourceExperimental — accuracy not yet measured
The paper’s full text (indexed under Abstract; no page supplied) supports NLRP3 activation in response to asbestos, silica, ATP and monosodium urate crystals, and implicates ROS and reduced intracellular K+ in activation. It does not address mitochondrial DNA, protein aggregates, ceramide, bacterial or viral RNA, reduced Cl−, or Ca2+ flux. It also describes direct interaction with NLRP3 as an unresolved hypothesis, rather than establishing direct activation by the listed signals. (LLM, conf=0.90)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
108 more claims · 73 with their cited sources checked
Create a free account to see all 218 claims and every source verdict.
- Probably not a substantial claim. 20
- It may state two separate claims as one. 93
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“The NLRP3 inflammasome activates caspase-1 through its assembly and activation processes. Activated caspase-1 can cleave gasdermin D (GSDMD), triggering pyroptosis and releasing IL-1β, IL-18, and ASC specks into the extracellular environment. This may exacerbate the spread of inflammation and neuronal death.246–249”
From Recent advances in Alzheimer's disease: Mechanisms, clinical trials and new drug development strategies. (2024) · cites this paper as [248]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Microglial function, INPP5D/SHIP1 signaling, and NLRP3 inflammasome activation: implications for Alzheimer’s disease > SHIP1 regulates microglia function and activation > Phosphoinositide signaling in AD
“PI(3,4,5)P3 can be converted back to PI(4,5)P2 by the protein phosphatase and tensin homology (PTEN) or converted into PI(3,4)P2 by SHIP1”
§ Microglial function, INPP5D/SHIP1 signaling, and NLRP3 inflammasome activation: implications for Alzheimer’s disease > SHIP1 regulates microglia function and activation > Phosphoinositide signaling in AD
“SHIP1 binds to PI(3,4,5)P3 via its PH-L domain and dephosphorylates PI(3,4,5)P3 via its 5’ phosphatase catalytic domain to generate PI(4,5)P2.”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Microglial function, INPP5D/SHIP1 signaling, and NLRP3 inflammasome activation: implications for Alzheimer’s disease > SHIP1 regulates microglia function and activation > SHIP1 modulates downstream activity of multiple receptors involved in microglia activation and function
“Upon binding to PI(3,4,5)P3, the 5’ phosphatase catalytic domain phosphorylates PI(3,4,5)P3 to generate PI(3,4)P2”
§ Microglial function, INPP5D/SHIP1 signaling, and NLRP3 inflammasome activation: implications for Alzheimer’s disease > SHIP1 regulates microglia function and activation > Phosphoinositide signaling in AD
“SHIP1 binds to PI(3,4,5)P3 via its PH-L domain and dephosphorylates PI(3,4,5)P3 via its 5’ phosphatase catalytic domain to generate PI(4,5)P2.”
Citations
Cites
NF-κB signaling in inflammation
Liu, T., Zhang, L., Joo, D., & Sun, S.-C. (2017) · Signal Transduction and Targeted Therapy · doi:10.1038/sigtrans.2017.23 · Cited by 8,791
Neurotoxic reactive astrocytes are induced by activated microglia
Liddelow, S. A., Guttenplan, K. A., Clarke, L. E., Bennett, F. C., Bohlen, C. J., Schirmer, L., Bennett, M. L., Münch, A. E., Chung, W.-S., Peterson, T. C., et al. (2017) · Nature · doi:10.1038/nature21029 · Cited by 7,971 · cited 2×
“Microglial activation or inflammatory insults induce astrocytes into a reactive state, which can have both neuroprotective and neurotoxic effects [17, 183–185].”
BackgroundThe amyloid hypothesis of Alzheimer's disease at 25 years
Selkoe, D. J., & Hardy, J. (2016) · EMBO Molecular Medicine · doi:10.15252/emmm.201606210 · Cited by 6,164
Alzheimer's Disease: Genes, Proteins, and Therapy
Selkoe, D. J. (2001) · Physiological Reviews · doi:10.1152/physrev.2001.81.2.741 · Cited by 6,063
A Unique Microglia Type Associated with Restricting Development of Alzheimer’s Disease
Keren-Shaul, H., Spinrad, A., Weiner, A., Matcovitch-Natan, O., Dvir-Szternfeld, R., Ulland, T. K., David, E., Baruch, K., Lara-Astaiso, D., Toth, B., et al. (2017) · Cell · doi:10.1016/j.cell.2017.05.018 · Cited by 5,493
Schroder, K., & Tschopp, J. (2010) · Cell · doi:10.1016/j.cell.2010.01.040 · Cited by 5,475
The senescence-associated secretory phenotype: the dark side of tumor suppression
Coppé, J.-P., Desprez, P.-Y., Krtolica, A., & Campisi, J. (2010) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev-pathol-121808-102144 · Cited by 5,206
The NLRP3 inflammasome: molecular activation and regulation to therapeutics
Swanson, K. V., Deng, M., & Ting, J. P.-Y. (2019) · Nature Reviews Immunology · doi:10.1038/s41577-019-0165-0 · Cited by 4,884
Zhang, Y., Chen, K., Sloan, S. A., Bennett, M. L., Scholze, A. R., O'Keeffe, S., Phatnani, H. P., Guarnieri, P., Caneda, C., Ruderisch, N., et al. (2014) · The Journal of Neuroscience · doi:10.1523/jneurosci.1860-14.2014 · Cited by 4,875 · cited 1×
“In the brain, expression of SHIP1 is primarily restricted to microglia [105].”
BackgroundMeta-Analysis of 74,046 Individuals Identifies 11 New Susceptibility Loci for Alzheimer’s Disease
(EADI), E. A. D. I., Lambert, J.-C., (GERAD), G. A. E. R. I. A. D., Alzheimer's Disease Genetic Consortium (ADGC), (CHARGE), C. F. H. A. A. R. I. G. E., Ibrahim-Verbaas, C. A., Harold, D., Naj, A. C., Sims, R., Bellenguez, C., et al. (2013) · Nature Genetics · doi:10.1038/ng.2802 · Cited by 4,336
Cited by
Zhang, J., Zhang, Y., Wang, J., Xia, Y., Zhang, J., & Chen, L. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01911-3 · Cited by 1,138
Decoding microglial immunometabolism: a new frontier in Alzheimer's disease research
Jung, E. S., Choi, H., & Mook-Jung, I. (2025) · Molecular Neurodegeneration · doi:10.1186/s13024-025-00825-0 · Cited by 124
AmeliMojarad, M., & AmeliMojarad, M. (2024) · CNS Neuroscience & Therapeutics · doi:10.1111/cns.14856 · Cited by 73
Pocock, J., Vasilopoulou, F., Svensson, E., & Cosker, K. (2024) · Neuropharmacology · doi:10.1016/j.neuropharm.2024.110020 · Cited by 54
Inflammasomes in neurodegenerative diseases
Wang, Q., Yang, S., Zhang, X., Zhang, S., Chen, L., Wang, W., Chen, N., & Yan, J. (2024) · Translational Neurodegeneration · doi:10.1186/s40035-024-00459-0 · Cited by 51
Metadata
- Authors
- Terzioglu, G., & Young-Pearse, T. L.
- Venue
- Molecular Neurodegeneration
- Published
- 2023-11-29
- Volume
- 18
- Issue
- 1
- Pages
- 89-89
- ISSN
- 1750-1326 (ISSN-L)
- PMC
- PMC10685641
- OpenAlex
- W4389109479
- Cited by
- 91
- References
- 200
- Citations by year
- 2026: 32 · 2025: 35 · 2024: 24
- FWCI
- 2.27
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Locations
- Molecular Neurodegeneration (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- NIH (R01AG055909, RF1NS117446, U01AG072572)
- Topics
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Inflammasome and immune disorders
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Keywords
- Alzheimer's disease, microglia, SHIP1, INPP5D, NLRP3 inflammasome, microglial phagocytosis, TREM2, phosphoinositide signaling, neuroinflammation, innate immunity
- MeSH terms
- NLR Family, Pyrin Domain-Containing 3 Protein, Phosphatidylinositol-3,4,5-Trisphosphate 5-Phosphatases, Alzheimer Disease, Brain, Humans, Microglia, Inflammasomes
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-18, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-18 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Microglial function, INPP5D/SHIP1 signaling, and NLRP3 inflammasome activation: implications for Alzheimer’s disease. https://app.cochat.ai/papers/10.1186/s13024-023-00674-9
- The paper
- Terzioglu, G., & Young-Pearse, T. L. (2023). Microglial function, INPP5D/SHIP1 signaling, and NLRP3 inflammasome activation: implications for Alzheimer’s disease. Molecular Neurodegeneration. https://doi.org/10.1186/s13024-023-00674-9
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.